June 9, 2020 -- Innovent Biologics has entered into a research and development collaboration with Roche for multiple cell therapies and bispecific antibodies.
The collaboration will focus on the discovery, clinical development, and commercialization of bispecific antibodies (antibodies that simultaneously bind separate and unique antigens) and multiple cell therapies. These therapies will be targeted for the treatment of hematological and solid cancers.
Under the agreement, Innovent will pay development and commercial milestone payments and royalties upfront to nonexclusively access certain Roche technologies that enable the discovery and development of 2:1 T-cell bispecific antibodies and a universal chimeric antigen receptor-T (CAR-T) cell platform.
Innovent will create, develop, manufacture, and commercialize the products. Roche retains the right to license each product for development outside of China.